Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
LaFleur Minerals Appoints Andrew Elinesky as Chief Executive Officer and Provides Update on Beacon Gold Mill Recommissioning Work and Swanson Bulk Sample Progress
